Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
AbbVie sees FY22 EPS $13.78-$13.98, consensus $14.01  16:24
07/06/22
07/06
16:24
07/06/22
16:24
ABBV

AbbVie

$152.65 /

-1.18 (-0.77%)

 
ShowHide Related Items >><<
ABBV AbbVie
$152.65 /

-1.18 (-0.77%)

ABBV AbbVie
$152.65 /

-1.18 (-0.77%)

05/23/22 SVB Securities
AbbVie initiated with an Underperform at SVB Leerink
05/13/22 Piper Sandler
Atopic dermatitis market looks 'increasingly crowded,' says Piper Sandler
05/06/22 Daiwa
AbbVie downgraded to Neutral from Outperform at Daiwa
05/03/22 Morgan Stanley
Vertex upgraded to Equal Weight at Morgan Stanley following AbbVie failure
ABBV AbbVie
$152.65 /

-1.18 (-0.77%)

ABBV AbbVie
$152.65 /

-1.18 (-0.77%)

ABBV AbbVie
$152.65 /

-1.18 (-0.77%)

ABBV AbbVie
$152.65 /

-1.18 (-0.77%)

Earnings
AbbVie sees Q2 $3.24-$3.28, consensus $3.43 » 16:24
07/06/22
07/06
16:24
07/06/22
16:24
ABBV

AbbVie

$152.65 /

-1.18 (-0.77%)

The company states:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ABBV AbbVie
$152.65 /

-1.18 (-0.77%)

ABBV AbbVie
$152.65 /

-1.18 (-0.77%)

05/23/22 SVB Securities
AbbVie initiated with an Underperform at SVB Leerink
05/13/22 Piper Sandler
Atopic dermatitis market looks 'increasingly crowded,' says Piper Sandler
05/06/22 Daiwa
AbbVie downgraded to Neutral from Outperform at Daiwa
05/03/22 Morgan Stanley
Vertex upgraded to Equal Weight at Morgan Stanley following AbbVie failure
ABBV AbbVie
$152.65 /

-1.18 (-0.77%)

ABBV AbbVie
$152.65 /

-1.18 (-0.77%)

ABBV AbbVie
$152.65 /

-1.18 (-0.77%)

ABBV AbbVie
$152.65 /

-1.18 (-0.77%)

Hot Stocks
FDA revises Emergency Use Authorization for Paxlovid » 12:43
07/06/22
07/06
12:43
07/06/22
12:43
PFE

Pfizer

$51.92 /

+0.275 (+0.53%)

The U.S. Food and Drug…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PFE Pfizer
$51.92 /

+0.275 (+0.53%)

PFE Pfizer
$51.92 /

+0.275 (+0.53%)

06:26 Today Evercore ISI
Enanta upgraded to Outperform at Evercore ISI ahead of COVID anti-viral data
07/01/22 RBC Capital
Enanta price target raised to $67 from $64 at RBC Capital
06/29/22 Evercore ISI
Icosavax upgraded to Outperform at Evercore on 'competitive' RSV vaccine data
06/22/22 Piper Sandler
Enanta's lawsuit against Pfizer 'not surprising,' says Piper Sandler
PFE Pfizer
$51.92 /

+0.275 (+0.53%)

PFE Pfizer
$51.92 /

+0.275 (+0.53%)

PFE Pfizer
$51.92 /

+0.275 (+0.53%)

PFE Pfizer
$51.92 /

+0.275 (+0.53%)

Hot Stocks
Pfizer announces non-exclusive patent license agreement with Touchlight » 10:36
07/06/22
07/06
10:36
07/06/22
10:36
PFE

Pfizer

$52.43 /

+0.79 (+1.53%)

Touchlight, a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PFE Pfizer
$52.43 /

+0.79 (+1.53%)

PFE Pfizer
$52.43 /

+0.79 (+1.53%)

06:26 Today Evercore ISI
Enanta upgraded to Outperform at Evercore ISI ahead of COVID anti-viral data
07/01/22 RBC Capital
Enanta price target raised to $67 from $64 at RBC Capital
06/29/22 Evercore ISI
Icosavax upgraded to Outperform at Evercore on 'competitive' RSV vaccine data
06/22/22 Piper Sandler
Enanta's lawsuit against Pfizer 'not surprising,' says Piper Sandler
PFE Pfizer
$52.43 /

+0.79 (+1.53%)

PFE Pfizer
$52.43 /

+0.79 (+1.53%)

PFE Pfizer
$52.43 /

+0.79 (+1.53%)

PFE Pfizer
$52.43 /

+0.79 (+1.53%)

Upgrade
Enanta upgraded to Outperform at Evercore ISI ahead of COVID anti-viral data » 06:26
07/06/22
07/06
06:26
07/06/22
06:26
ENTA

Enanta

/

+

, PFE

Pfizer

$51.64 /

-0.695 (-1.33%)

Evercore ISI analyst…

Evercore ISI analyst Liisa Bayko upgraded Enanta (ENTA) to Outperform from In Line with a $62 price target, telling investors that she believes the Phase 1 first-in-human data for its COVID anti-viral data due in July will show that its once-daily COVID protease inhibitor, EDP-235, doesn't require ritonavir to reach exposures needed for a strong anti-viral effect like Pfizer's (PFE) Paxlovid does. The anti-viral "could be best in class and partnerable," added Bayko, who is assuming a 20% probability of success for EDP-235 being commercialized by a pharma partner.

ShowHide Related Items >><<
PFE Pfizer
$51.64 /

-0.695 (-1.33%)

ENTA Enanta
/

+

ENTA Enanta
/

+

06:15 Today Evercore ISI
Enanta upgraded to Outperform from In Line at Evercore ISI
07/01/22 RBC Capital
Enanta price target raised to $67 from $64 at RBC Capital
06/22/22 Piper Sandler
Enanta's lawsuit against Pfizer 'not surprising,' says Piper Sandler
05/31/22 Evercore ISI
Enanta upgraded to In Line from Underperform at Evercore ISI
PFE Pfizer
$51.64 /

-0.695 (-1.33%)

06/29/22 Evercore ISI
Icosavax upgraded to Outperform at Evercore on 'competitive' RSV vaccine data
06/13/22 Morgan Stanley
Moderna pediatric EUA vaccine briefing docs 'clean,' says Morgan Stanley
PFE Pfizer
$51.64 /

-0.695 (-1.33%)

ENTA Enanta
/

+

PFE Pfizer
$51.64 /

-0.695 (-1.33%)

PFE Pfizer
$51.64 /

-0.695 (-1.33%)

ENTA Enanta
/

+

PFE Pfizer
$51.64 /

-0.695 (-1.33%)

Yesterday
Recommendations
Stifel says 'logical to assume' Walgreens could look at 1Life Healthcare » 16:12
07/05/22
07/05
16:12
07/05/22
16:12
ONEM

1Life Healthcare

$10.32 /

+2.065 (+25.02%)

, CVS

CVS Health

$92.56 /

-1.25 (-1.33%)

, WBA

Walgreens Boots Alliance

$38.50 /

-0.085 (-0.22%)

, UNH

UnitedHealth

$505.29 /

-11.83 (-2.29%)

, HUM

Humana

$472.96 /

-5.62 (-1.17%)

, CI

Cigna

$264.81 /

-3.16 (-1.18%)

, CNC

Centene

$84.68 /

-1.43 (-1.66%)

Stifel analyst Craig…

Stifel analyst Craig Jones noted that Bloomberg reported that 1Life Healthcare (ONEM) is considering potential takeover offers after receiving interest from CVS Health (CVS) and others, though the report said CVS is no longer interested and no other companies were mentioned by name. If CVS were interested, it is "logical to assume" Walgreens (WBA) would be as well, according to Jones, who adds that the payor group - including UnitedHealth (UNH), Humana (HUM), Cigna (CI) and Centene (CNC) - would be among other "logical acquirers." Jones keeps a Buy rating and $12 price target on 1Life Healthcare shares, which closed up nearly 25% at $10.34.

ShowHide Related Items >><<
WBA Walgreens Boots Alliance
$38.50 /

-0.085 (-0.22%)

UNH UnitedHealth
$505.29 /

-11.83 (-2.29%)

ONEM 1Life Healthcare
$10.32 /

+2.065 (+25.02%)

HUM Humana
$472.96 /

-5.62 (-1.17%)

CVS CVS Health
$92.56 /

-1.25 (-1.33%)

CNC Centene
$84.68 /

-1.43 (-1.66%)

CI Cigna
$264.81 /

-3.16 (-1.18%)

ONEM 1Life Healthcare
$10.32 /

+2.065 (+25.02%)

06/16/22 Deutsche Bank
1Life Healthcare market cap now below last private raise, says Deutsche Bank
05/26/22 Stifel
1Life Healthcare initiated with a Buy at Stifel
05/24/22 Piper Sandler
1Life Healthcare price target lowered to $15 from $20 at Piper Sandler
05/06/22 Deutsche Bank
1Life Healthcare price target lowered to $11 from $16 at Deutsche Bank
CVS CVS Health
$92.56 /

-1.25 (-1.33%)

06/16/22 Loop Capital
Loop Capital starts CVS Health at Buy citing position to capitalize on Medicare
06/16/22 Loop Capital
CVS Health initiated with a Buy at Loop Capital
06/03/22 Morgan Stanley
CVS deal a 'game-changer' for Amwell's Converge, says Morgan Stanley
05/26/22 Bernstein
CVS Health downgraded to Market Perform from Outperform at Bernstein
WBA Walgreens Boots Alliance
$38.50 /

-0.085 (-0.22%)

07/05/22 RBC Capital
Walgreens Boots Alliance price target lowered to $42 from $46 at RBC Capital
07/01/22 Morgan Stanley
Walgreens consensus needs to come down by more than 11%, says Morgan Stanley
07/01/22 Credit Suisse
Walgreens Boots Alliance price target lowered to $43 from $52 at Credit Suisse
07/01/22 Deutsche Bank
Walgreens Boots Alliance price target lowered to $44 from $46 at Deutsche Bank
UNH UnitedHealth
$505.29 /

-11.83 (-2.29%)

06/16/22 Loop Capital
Loop starts UnitedHealth at Buy, sees company having 'major' advantages
06/16/22 Loop Capital
UnitedHealth initiated with a Buy at Loop Capital
06/01/22 Citi
Change Healthcare price target raised to $27.75 from $25.75 at Citi
05/26/22 Bernstein
UnitedHealth downgraded to Market Perform at Bernstein on valuation
HUM Humana
$472.96 /

-5.62 (-1.17%)

06/16/22 Loop Capital
Loop starts Humana at Buy on brand and growing portfolio
06/16/22 Loop Capital
Humana initiated with a Buy at Loop Capital
05/26/22 Bernstein
Humana resumed with a Market Perform at Bernstein
04/28/22 Wells Fargo
Humana price target raised to $512 from $491 at Wells Fargo
CI Cigna
$264.81 /

-3.16 (-1.18%)

06/22/22 Morgan Stanley
Anthem downgraded to Equal Weight from Overweight at Morgan Stanley
06/22/22 Morgan Stanley
Cigna upgraded to Overweight from Equal Weight at Morgan Stanley
06/16/22 Loop Capital
Loop starts Cigna at Hold, says major reclassifications now 'behind us'
06/16/22 Loop Capital
Cigna initiated with a Hold at Loop Capital
CNC Centene
$84.68 /

-1.43 (-1.66%)

06/22/22 Deutsche Bank
Centene price target raised to $91 from $88 at Deutsche Bank
06/21/22 Credit Suisse
Centene upgraded to Outperform from Neutral at Credit Suisse
06/16/22 Loop Capital
Loop Capital starts Centene at Buy on greater profitability, shareholder returns
06/16/22 Loop Capital
Centene initiated with a Buy at Loop Capital
WBA Walgreens Boots Alliance
$38.50 /

-0.085 (-0.22%)

UNH UnitedHealth
$505.29 /

-11.83 (-2.29%)

ONEM 1Life Healthcare
$10.32 /

+2.065 (+25.02%)

HUM Humana
$472.96 /

-5.62 (-1.17%)

CVS CVS Health
$92.56 /

-1.25 (-1.33%)

CNC Centene
$84.68 /

-1.43 (-1.66%)

CI Cigna
$264.81 /

-3.16 (-1.18%)

WBA Walgreens Boots Alliance
$38.50 /

-0.085 (-0.22%)

UNH UnitedHealth
$505.29 /

-11.83 (-2.29%)

ONEM 1Life Healthcare
$10.32 /

+2.065 (+25.02%)

HUM Humana
$472.96 /

-5.62 (-1.17%)

CVS CVS Health
$92.56 /

-1.25 (-1.33%)

CNC Centene
$84.68 /

-1.43 (-1.66%)

CI Cigna
$264.81 /

-3.16 (-1.18%)

WBA Walgreens Boots Alliance
$38.50 /

-0.085 (-0.22%)

UNH UnitedHealth
$505.29 /

-11.83 (-2.29%)

ONEM 1Life Healthcare
$10.32 /

+2.065 (+25.02%)

HUM Humana
$472.96 /

-5.62 (-1.17%)

CVS CVS Health
$92.56 /

-1.25 (-1.33%)

CNC Centene
$84.68 /

-1.43 (-1.66%)

CI Cigna
$264.81 /

-3.16 (-1.18%)

WBA Walgreens Boots Alliance
$38.50 /

-0.085 (-0.22%)

UNH UnitedHealth
$505.29 /

-11.83 (-2.29%)

ONEM 1Life Healthcare
$10.32 /

+2.065 (+25.02%)

HUM Humana
$472.96 /

-5.62 (-1.17%)

CVS CVS Health
$92.56 /

-1.25 (-1.33%)

CNC Centene
$84.68 /

-1.43 (-1.66%)

CI Cigna
$264.81 /

-3.16 (-1.18%)

Conference/Events
Cantor Fitzgerald biotech/pharma analysts hold analyst/industry conference call » 14:12
07/05/22
07/05
14:12
07/05/22
14:12
JNJ

Johnson & Johnson

$176.53 /

-3.02 (-1.68%)

, ABBV

AbbVie

$152.37 /

-1.34 (-0.87%)

, PFE

Pfizer

$51.00 /

-1.335 (-2.55%)

, REGN

Regeneron

$586.16 /

-8.62 (-1.45%)

, AMGN

Amgen

$244.57 /

-0.76 (-0.31%)

, INCY

Incyte

$78.05 /

+0.36 (+0.46%)

, ROIV

Roivant Sciences

$4.50 /

+0.075 (+1.70%)

Biopharma & Biotech…

Biopharma & Biotech Analyst Chen, Biotech Analyst Agrawal and Biopharma Analyst Kim, along with Felix Urman, Asst Professor at Icahn School of Medicine, discuss new and emerging treatments for Atopic Dermatitis and Psoriasis, including JNJ's Tremfya, ABBV's Skyrizi, PFE's Eucrisa, REGN's Dupixent, AMGN's Otezla, INCY's Opzelura and ROIV's Vtama on an Analyst/Industry conference call to be held on July 14 at 1 pm.

ShowHide Related Items >><<
ROIV Roivant Sciences
$4.50 /

+0.075 (+1.70%)

REGN Regeneron
$586.16 /

-8.62 (-1.45%)

PFE Pfizer
$51.00 /

-1.335 (-2.55%)

JNJ Johnson & Johnson
$176.53 /

-3.02 (-1.68%)

INCY Incyte
$78.05 /

+0.36 (+0.46%)

AMGN Amgen
$244.57 /

-0.76 (-0.31%)

ABBV AbbVie
$152.37 /

-1.34 (-0.87%)

JNJ Johnson & Johnson
$176.53 /

-3.02 (-1.68%)

06/22/22 Daiwa
Johnson & Johnson initiated with an Outperform at Daiwa
05/27/22 Needham
Needham upgrades Boston Scientific to Buy, sees stock as potential M&A target
05/23/22 SVB Securities
Johnson & Johnson assumed with an Outperform at SVB Leerink
05/17/22 BofA
Teva upgraded to Neutral at BofA on potential opioid deal upside
ABBV AbbVie
$152.37 /

-1.34 (-0.87%)

05/23/22 SVB Securities
AbbVie initiated with an Underperform at SVB Leerink
05/13/22 Piper Sandler
Atopic dermatitis market looks 'increasingly crowded,' says Piper Sandler
05/06/22 Daiwa
AbbVie downgraded to Neutral from Outperform at Daiwa
05/03/22 Morgan Stanley
Vertex upgraded to Equal Weight at Morgan Stanley following AbbVie failure
PFE Pfizer
$51.00 /

-1.335 (-2.55%)

07/01/22 RBC Capital
Enanta price target raised to $67 from $64 at RBC Capital
06/29/22 Evercore ISI
Icosavax upgraded to Outperform at Evercore on 'competitive' RSV vaccine data
06/22/22 Piper Sandler
Enanta's lawsuit against Pfizer 'not surprising,' says Piper Sandler
06/13/22 Morgan Stanley
Moderna pediatric EUA vaccine briefing docs 'clean,' says Morgan Stanley
REGN Regeneron
$586.16 /

-8.62 (-1.45%)

06/24/22 Chardan
Intellia durability data for NTLA-2001 'looking good so far,' says Chardan
06/06/22 Jefferies
Regeneron initiated with an Underperform at Jefferies
06/02/22 Piper Sandler
Regeneron selloff on Libtayo deal overdone, says Piper Sandler
05/31/22 Argus
Regeneron price target raised to $760 from $680 at Argus
AMGN Amgen
$244.57 /

-0.76 (-0.31%)

06/07/22 Stifel
Mirati Therapeutics price target raised to $111 from $105 at Stifel
06/01/22 Oppenheimer
Amgen price target raised to $290 from $285 at Oppenheimer
05/27/22 Stifel
Mirati Therapeutics after-hours move lower 'overdone,' says Stifel
05/23/22 SVB Securities
Radius Health initiated with a Market Perform at SVB Leerink
INCY Incyte
$78.05 /

+0.36 (+0.46%)

05/03/22 Stifel
Incyte price target raised to $77 from $75 at Stifel
02/09/22 SVB Securities
SVB Leerink downgrades Incyte to Underperform, lowers price target to $56
02/09/22 SVB Securities
Incyte downgraded to Underperform from Market Perform at SVB Leerink
01/18/22 RBC Capital
Incyte upgraded to Outperform at RBC Capital on improving 2022 setup
ROIV Roivant Sciences
$4.50 /

+0.075 (+1.70%)

05/23/22 SVB Securities
Roivant Sciences initiated with an Outperform at SVB Leerink
04/29/22 Cantor Fitzgerald
Roivant Sciences initiated with an Overweight at Cantor Fitzgerald
12/15/21 Goldman Sachs
Roivant Sciences initiated with a Buy at Goldman Sachs
12/02/21 H.C. Wainwright
H.C. Wainwright says Arbutus patent win may mean 'considerable gain' for Roivant
ROIV Roivant Sciences
$4.50 /

+0.075 (+1.70%)

REGN Regeneron
$586.16 /

-8.62 (-1.45%)

PFE Pfizer
$51.00 /

-1.335 (-2.55%)

JNJ Johnson & Johnson
$176.53 /

-3.02 (-1.68%)

INCY Incyte
$78.05 /

+0.36 (+0.46%)

AMGN Amgen
$244.57 /

-0.76 (-0.31%)

ABBV AbbVie
$152.37 /

-1.34 (-0.87%)

REGN Regeneron
$586.16 /

-8.62 (-1.45%)

PFE Pfizer
$51.00 /

-1.335 (-2.55%)

JNJ Johnson & Johnson
$176.53 /

-3.02 (-1.68%)

ABBV AbbVie
$152.37 /

-1.34 (-0.87%)

ROIV Roivant Sciences
$4.50 /

+0.075 (+1.70%)

REGN Regeneron
$586.16 /

-8.62 (-1.45%)

PFE Pfizer
$51.00 /

-1.335 (-2.55%)

JNJ Johnson & Johnson
$176.53 /

-3.02 (-1.68%)

INCY Incyte
$78.05 /

+0.36 (+0.46%)

AMGN Amgen
$244.57 /

-0.76 (-0.31%)

ABBV AbbVie
$152.37 /

-1.34 (-0.87%)

ROIV Roivant Sciences
$4.50 /

+0.075 (+1.70%)

PFE Pfizer
$51.00 /

-1.335 (-2.55%)

JNJ Johnson & Johnson
$176.53 /

-3.02 (-1.68%)

AMGN Amgen
$244.57 /

-0.76 (-0.31%)

ABBV AbbVie
$152.37 /

-1.34 (-0.87%)

Conference/Events
Cantor Fitzgerald pharmaceuticals analysts hold analyst/industry conference call » 13:45
07/05/22
07/05
13:45
07/05/22
13:45
PFE

Pfizer

$50.73 /

-1.605 (-3.07%)

, ARVN

Arvinas

$45.28 /

+2.75 (+6.47%)

Pharmaceuticals Analysts…

Pharmaceuticals Analysts discuss new and emerging treatments for breast cancer and the debate surrounding Pfizer/Arvinas's ARV-471 Analyst/Industry conference call to be held on July 14 at 11 am.

ShowHide Related Items >><<
PFE Pfizer
$50.73 /

-1.605 (-3.07%)

ARVN Arvinas
$45.28 /

+2.75 (+6.47%)

PFE Pfizer
$50.73 /

-1.605 (-3.07%)

07/01/22 RBC Capital
Enanta price target raised to $67 from $64 at RBC Capital
06/29/22 Evercore ISI
Icosavax upgraded to Outperform at Evercore on 'competitive' RSV vaccine data
06/22/22 Piper Sandler
Enanta's lawsuit against Pfizer 'not surprising,' says Piper Sandler
06/13/22 Morgan Stanley
Moderna pediatric EUA vaccine briefing docs 'clean,' says Morgan Stanley
ARVN Arvinas
$45.28 /

+2.75 (+6.47%)

05/23/22 Piper Sandler
Arvinas price target lowered to $76 from $116 at Piper Sandler
05/09/22 Wedbush
Wedbush downgrades Arvinas to Neutral, cuts price target to $43
05/09/22 Wedbush
Arvinas downgraded to Neutral from Outperform at Wedbush
05/06/22 Cantor Fitzgerald
Arvinas assumed with an Overweight at Cantor Fitzgerald
PFE Pfizer
$50.73 /

-1.605 (-3.07%)

ARVN Arvinas
$45.28 /

+2.75 (+6.47%)

PFE Pfizer
$50.73 /

-1.605 (-3.07%)

PFE Pfizer
$50.73 /

-1.605 (-3.07%)

ARVN Arvinas
$45.28 /

+2.75 (+6.47%)

PFE Pfizer
$50.73 /

-1.605 (-3.07%)

Hot Stocks
CureVac files patent infringement suit in Germany against BioNTech » 07:20
07/05/22
07/05
07:20
07/05/22
07:20
CVAC

CureVac

$14.21 /

+0.5 (+3.65%)

, BNTX

BioNTech

$157.48 /

+8.545 (+5.74%)

, PFE

Pfizer

$52.33 /

-0.18 (-0.34%)

CureVac N.V. (CVAC)…

CureVac N.V. (CVAC) announced that it has moved to assert its intellectual property rights, accumulated over more than two decades of pioneering work in mRNA technology, which contributed to COVID-19 vaccine development. CureVac has filed a lawsuit in the German Regional Court in Dusseldorf against BioNTech (BNTX) and two of its subsidiaries, seeking fair compensation for infringement of a portfolio of CureVac's intellectual property rights, EP 1 857 122 B1, DE 20 2015 009 961 U1, DE 20 2021 003 575 U1 and DE 20 2015 009 974 U1, utilized in the manufacture and sale of Comirnaty, BioNTech and Pfizer's (PFE) mRNA COVID-19 vaccine. CureVac does not seek an injunction nor intend to take legal action that impedes the production, sale or distribution of Comirnaty by BioNTech and its partner Pfizer. The company said, "The CureVac intellectual property portfolio protects multiple inventions that are considered essential to the design and development of BioNTech's SARS CoV-2 mRNA vaccine, among others. These relate to the engineering of mRNA molecules, including sequence modifications to increase stability and enhance protein expression, as well as mRNA vaccine formulations specific to SARS CoV-2 vaccines. Over the last 22 years, CureVac developed proprietary foundational technology related to mRNA design, delivery and manufacturing that materially contributed to the development of safe and efficacious COVID-19 vaccines. CureVac considers the rapid development of these vaccines a tremendous achievement, with unprecedented positive impact for global public health. This achievement is based on decades of scientific research and innovation, supported by CureVac as the earliest pioneer in mRNA technology. Accordingly, CureVac's intellectual property rights need to be acknowledged and respected in the form of a fair compensation to reinvest into the further advancement of mRNA technology and the ongoing development of new classes of life saving medicines."

ShowHide Related Items >><<
PFE Pfizer
$52.33 /

-0.18 (-0.34%)

CVAC CureVac
$14.21 /

+0.5 (+3.65%)

BNTX BioNTech
$157.48 /

+8.545 (+5.74%)

CVAC CureVac
$14.21 /

+0.5 (+3.65%)

01/21/22 BofA
CureVac cut to Underperform at BofA on limited catalyst flow this year
01/21/22 BofA
CureVac downgraded to Underperform from Neutral at BofA
01/18/22 JMP Securities
CureVac initiated with an Outperform at JMP Securities
12/22/21 Kempen
CureVac downgraded to Sell from Neutral at Kempen
BNTX BioNTech
$157.48 /

+8.545 (+5.74%)

06/13/22 Morgan Stanley
Moderna pediatric EUA vaccine briefing docs 'clean,' says Morgan Stanley
04/12/22 H.C. Wainwright
BioNTech price target lowered to $298 from $339 at H.C. Wainwright
04/11/22 H.C. Wainwright
H.C. Wainwright bullish on Matinas as LNC platform attracts BioNTech collab
04/05/22 Canaccord
BioNTech price target lowered to $300 from $450 at Canaccord
PFE Pfizer
$52.33 /

-0.18 (-0.34%)

07/01/22 RBC Capital
Enanta price target raised to $67 from $64 at RBC Capital
06/29/22 Evercore ISI
Icosavax upgraded to Outperform at Evercore on 'competitive' RSV vaccine data
06/22/22 Piper Sandler
Enanta's lawsuit against Pfizer 'not surprising,' says Piper Sandler
PFE Pfizer
$52.33 /

-0.18 (-0.34%)

CVAC CureVac
$14.21 /

+0.5 (+3.65%)

BNTX BioNTech
$157.48 /

+8.545 (+5.74%)

BNTX BioNTech
$157.48 /

+8.545 (+5.74%)

CVAC CureVac
$14.21 /

+0.5 (+3.65%)

BNTX BioNTech
$157.48 /

+8.545 (+5.74%)

PFE Pfizer
$52.33 /

-0.18 (-0.34%)

BNTX BioNTech
$157.48 /

+8.545 (+5.74%)

Friday
Recommendations
Enanta price target raised to $67 from $64 at RBC Capital » 09:17
07/01/22
07/01
09:17
07/01/22
09:17
ENTA

Enanta

$47.13 /

+0.255 (+0.54%)

, PFE

Pfizer

$52.52 /

+1.58 (+3.10%)

RBC Capital analyst Brian…

RBC Capital analyst Brian Abrahams raised the firm's price target on Enanta (ENTA) to $67 from $64 and keeps a Sector Perform rating on the shares. An IP specialist on Enanta's recent claims against Pfizer (PFE) regarding Paxlovid indicated that the company "has a reasonable case", the analyst tells investors in a research note. Given Pfizer's deep pockets and unique pandemic aspects, a settlement is possible, though it would likely take some time to play out, Abrahams adds.

ShowHide Related Items >><<
PFE Pfizer
$52.52 /

+1.58 (+3.10%)

ENTA Enanta
$47.13 /

+0.255 (+0.54%)

ENTA Enanta
$47.13 /

+0.255 (+0.54%)

06/22/22 Piper Sandler
Enanta's lawsuit against Pfizer 'not surprising,' says Piper Sandler
05/31/22 Evercore ISI
Enanta upgraded to In Line from Underperform at Evercore ISI
05/20/22 Oppenheimer
Enanta price target lowered to $45 from $70 at Oppenheimer
05/19/22 Roth Capital
Enanta study hints at efficacy despite miss, says Roth Capital
PFE Pfizer
$52.52 /

+1.58 (+3.10%)

06/29/22 Evercore ISI
Icosavax upgraded to Outperform at Evercore on 'competitive' RSV vaccine data
06/13/22 Morgan Stanley
Moderna pediatric EUA vaccine briefing docs 'clean,' says Morgan Stanley
06/03/22 Oppenheimer
Turning Point Therapeutics downgraded to Perform from Outperform at Oppenheimer
PFE Pfizer
$52.52 /

+1.58 (+3.10%)

ENTA Enanta
$47.13 /

+0.255 (+0.54%)

PFE Pfizer
$52.52 /

+1.58 (+3.10%)

PFE Pfizer
$52.52 /

+1.58 (+3.10%)

ENTA Enanta
$47.13 /

+0.255 (+0.54%)

PFE Pfizer
$52.52 /

+1.58 (+3.10%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.